期刊文献+

围心脏手术期被动肺动脉高压:从基础到临床

Passive pulmonary hypertension after cardiac surgery: from bench to bedside
原文传递
导出
摘要 由于左心房压力的升高而导致肺动脉压力升高称为被动肺高压(passive pulmonary hypertension,pPH),多由左心疾病导致,其实质是肺血容量增多,在PH分类中pPH属第二类。最近,我们小组鉴定出另一类pPH,它由血管收缩药物引起,与左心疾病导致的pPH有相似的病理生理表现,二者可以叠加而加重pPH。围心脏手术期,手术创伤导致的心脏功能不全时常使用血管收缩药物,因此临床中pPH的叠加现象可能极为普遍。然而,此类肺高压诊断困难而临床上对此认识不足而常被忽视。为增加对pPH的了解,减轻其临床危害,本文对两类pPH的病理生理及其叠加效应进行综述。 In left heart disease, pulmonary artery pressure would increase due to the elevated left atrial pressure.This type of pulmonary hypertension(PH) is belonged to type Ⅱ as a passive PH(pPH) in its classification. The essential cause of pPH is excessive blood volume. Recently, we have identified another type of pPH, which is induced by vasopressors. Vasopressor-induced pPH shares similar pathophysiological manifestations with left heart disease-induced pPH. pPH would, therefore, be aggressive if vasopressors were applied in patients with left heart disease, which may be common after cardiac surgery, because heart undergoing surgical trauma may require support of vasopressors.Unfortunately, pPH after cardiac surgery is often ignored because of the difficulty in diagnosis. To improve the understanding of pPH and its effect on outcomes, here we highlight the mechanisms of interaction between vasopressorinduced and left heart failure-induced pPH, and provide insights into its therapeutic options.
作者 谭赵霞 罗南富 秦臻 杜磊 TAN Zhaoxia;LUO Nanfu;QIN Zhen;DU Lei(Department of Anesthesiology, West China Hospital, Sichuan University, Chengdu, 610041, P.R. China)
出处 《中国胸心血管外科临床杂志》 CAS CSCD 2019年第6期601-605,共5页 Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
基金 国家自然科学基金资助项目(81570374) 四川省卫生计生委资助项目(17PJ214)
关键词 肺高压 被动性 左心疾病 血管活性药物 叠加效应 Pulmonary hypertension, passive left heart disease vasopressor agents additive effects
  • 相关文献

参考文献2

二级参考文献28

  • 1Laffey JG, Boylan JF, Cheng DC. The systemic inflammatory response to cardiac surgery: Implications for the anesthesiologist. Anesthesiology 2002;97:215-52.
  • 2Hall RI, Smith MS, Rocker G. The systemic inflammatory response to cardiopulmonary bypass: Pathophysiological, therapeutic, and pharmacological considerations. Anesth Analg 1997;85:766-82.
  • 3Ng CS, Wan S. Limiting inflammatory response to cardiopulmonary bypass: Pharmaceutical strategies. Curr Opin Pharmacol 2012;12:155-9.
  • 4Warren O J, Smith AJ, Alexiou C, Rogers PL, Jawad N, Vincent C, et aL The inflammatory response to cardiopulmonary bypass: Part 1 - Mechanisms of pathogenesis. J Cardiothorac Vasc Anesth 2009;23:223-31.
  • 5Vohra HA, Whistance R, Modi A, Ohri SK. The inflammatory response to miniaturised extracorporeal circulation: A review of the literature. Mediators Inflamm 2009;2009:707042.
  • 6Tang J, Tao K, Zhou J, Zhang C, Gong L, Luo N, et al. Long-term leukocyte filtration should be avoided during extracorporeal circulation. Mediators Inflamm 2013;2013:612848.
  • 7Nakanishi K, Takeda S, Sakamoto A, Kitamura A. Effects of ulinastatin treatment on the cardiopulmonary bypass-induced hemodynamic instability and pulmonary dysfunction. Crit Care Med 2006;34:1351-7.
  • 8Xu CE, Zou CW, Zhang MY, Guo L. Effects of high-dose ulinastatin on inflammatory response and pulmonary function in patients with type-A aortic dissection after eardiopulmonary bypass under deep hypothermic circulatory arrest. J Cardiothorac Vasc Anesth 2013;27:479-84.
  • 9Song J, Park J, Kim JY, Kim JD, Kang WS, Muhammad HB, et aL Effect of ulinastatin on perioperative organ function and systemic inflammatory reaction during cardiac surgery: A randomized double-blinded study. Korean J Anesthesiol 2013;64:334-40.
  • 10Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, et aL The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994;149 (3 Pt 1):818-24.

共引文献72

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部